tPA is currently given as a treatment for various CVDs and ARDS in COVID-19 [63, 64], whereas elevated PAI-1 is a risk factor for both thromboembolism and atherosclerosis [65]. The gene discussed is SERPINE1; the disease is Thromboembolism.